Comparative Pharmacology
Head-to-head clinical analysis: PRISCOLINE versus THEROXIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISCOLINE versus THEROXIDIL.
PRISCOLINE vs THEROXIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Priscoline (tolazoline) is a competitive alpha-adrenergic receptor antagonist; also has direct vasodilatory and histamine-like effects, leading to peripheral vasodilation and decreased peripheral vascular resistance.
Theroxidil is a vasodilator that acts by opening potassium channels in vascular smooth muscle, leading to hyperpolarization and relaxation. It also inhibits platelet aggregation and reduces peripheral vascular resistance.
10-50 mg subcutaneously or intramuscularly every 4-6 hours; intravenous administration (10 mg slow IV push) reserved for acute vasospastic episodes.
5 mg orally once daily, increased to 10 mg after 4 weeks as tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults; prolonged in renal impairment.
Terminal elimination half-life 24-30 hours; steady-state reached after 4-5 days; clinically significant for once-daily dosing
Primarily renal excretion of unchanged drug (approximately 90%); minor fecal excretion (<10%).
Approximately 60% renal (15% unchanged, 45% as glucuronide metabolites), 40% fecal/biliary as metabolites
Category C
Category C
Vasodilator
Vasodilator